Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | MSH6 loss |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03911557 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | Active, not recruiting | USA | 0 |
NCT02912559 | Phase III | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | Active, not recruiting | USA | DEU | 1 |
NCT04082572 | Phase II | Pembrolizumab | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | Completed | USA | 0 |
NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |